Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis

Table 3 Base case results for 5 statin treatment strategies in 100,000 hypothetical intermediate risk patients

Strategy	CVD (events, n)	RVSC (events, n)	Mild Adverse Events (n)	Severe Adverse Events (n)	Diabetes diagnoses (n)	Cost ($1000)	QALYs	Cost/QALY ($)	ΔCost ($1000)	ΔQALY	ICER
HST	2,527	2,252	5,600	37	1,107	258,460	460,516	561	−44,755^a	512^a	Dominant^b
Test-and-HST	3,177	2,646	5,600	37	442	298,547	460,119	649	−4,668^a	115^a	Dominant
MST	3,311	2,727	5,600	37	368	303,215	460,004	659	Reference	Reference
Test-and-MST	3,787	3,197	560	4	36	336,633	460,162	732	−3,246^c	44^c	Dominant^d
Do-not-treat	3,884	3,294	0	0	0	339,879	460,118	739	Reference	Reference

Care strategies: do-not-treat, no statin therapy; test-and-MST, moderate-intensity statin therapy for those in the top decile of LDL-P levels; MST, moderate-intensity statin therapy for all; test-and-HST, high-intensity statin therapy those in the top decile of LDL-P levels and moderate-intensity statin therapy for all other; HST, high-intensity statin therapy for all
CVD, cardiovascular disease, RVSC, revascularization
^aCompared with MST
^bDominates both MST and do-not-treat
^cCompared with do not treat
^dICER equals 211,456 ($/QALY) when compared with MST

ISSN: 1471-2261